February 27th 2024
Results of the study determined that adult flu vaccination rates among Medicaid populations were significantly low, highlighting other health inequities.
February 21st 2024
Researchers highlight several benefits and concerns associated with the launch of direct-to-consumer models for GLP-1 receptor agonists.
February 19th 2024
Amid shifting healthcare cost strategies, how manufacturers can apply past lessons to best support patients and help boost drug adherence.
February 15th 2024
A strategic formulation for separate IDN market spaces.
February 7th 2024
As the market for biosimilars expands, a nuanced approach is needed to balance cost considerations with patient safety and pharmacovigilance efforts.
Assessing HCP-Visit Fallout: COVID’s Ultimate Impact on New Drug Entrants
Tracking the pandemic’s influence on brand awareness and prescribing efforts in light of decline in physician visits and fewer diagnoses—and what these dynamics, still unsettled post-pandemic, might mean for future launches.
Closing the Gaps in Pre-Approval Information Exchange to Accelerate Product Success and Patient Access
Gaps remain in the pre-approval information process leave payers without all of the information they need to make the proper decisions.
A Cross-Functional Formula: Operationalizing the Broader Role of Access
The BCG Market Access Roundtable outlines the new and advanced access competencies required to enable functional operationalization and delivery of this critical role in biopharma—today a key strategic partner in achieving overall business goals.
The Price of Innovation: ‘Paying for a Cure’ Remains Costly Proposition
Curative-type therapies offer great hope in further transforming treatments for cancer and other diseases, but addressing the economics of these products—and ultimately the cost-benefit equation—is daunting. What is being done to smooth the path for pricing and reimbursement?
Payers Believe Lowering Drug Prices While Improving Patient Access Is Possible—but There’s a Catch
Value-based price for access (VBPA) may increase access of specialty drugs for patients.
Accelerating Market Access with Data-Driven Payer Engagement
Using data visualizations to improve access to payers.
When Will Payers Improve Coverage of Prescription Digital Therapeutics?
New MMIT research highlights payers’ continued hesitancy toward PDTs. Here’s what manufacturers need to know.
If Non-Formulary Hospital, Price May Not Be the Rx
Reversing non-formulary status will usually require new data.
Q&A With Chitkala Kalidas, vice president and global head, Bayer Oncology Regulatory Affairs and Oncology Sustainability
Kalidas spoke with Pharm Exec about her efforts to bring equity to underserved patients and their communities through Bayer’s Oncology Sustainability Initiative.
Real-World Evidence Is Becoming a Pivotal Component in Chinese Healthcare
Its use enables key processes such as early access, regulatory approval, and reimbursement listing.
Partnering to Respond to a Possible Nuclear Threat
Recent explosion at Zaporizhzhia nuclear power plant in Ukraine shows how pharma industry can pull together and take action in the face of adversity.
Prospective Measures to Combat Rising Drug Prices in Germany
This article provides an overview of potential tools being explored in Germany by Health Insurance Funds to better control drug prices and healthcare spend, offering insight into which measure may be implemented.
The Case for Elevating a Brand’s Price Proposition
Tackling the subjective limits of value proposition.
Why Patient-Centric Innovation Holds the Key to Long-Term Business Success for Companies in China’s Booming Biotech Sector
Assessing the road ahead for Chinese biotech.
Planning for Second to Market in Orphan Disease Space
Payers not looking to favor one product.
Partnerships Are Key to Niche Markets in Brazil
Forging effective partnerships with local companies is particularly important when entering Brazil’s pharma market. Sameer Kolhe reports.
Market Access Speed Is the Next Critical Differentiator for Pharma Manufacturers
New technology forces industry to increase urgency.
Playing the Long Game on Tighter Than Label Coverage
Potential for quality equivalent to economies of scale.
Could Time Be the Next New Element in Pharma Revenue?
Emerging limits of one-year payer time frames.
When Innovation Outpaces HTA, Access Struggles to Keep Up
Scientific advances are benefiting cancer patients, but it will take a pandemic-like response to ensure patients everywhere have access.
How Medical Affairs Can Contribute to Successful Drug Launch
Faster launch planning leads to greater access.
A Brave New World: Optimizing Access in Wake of COVID
The top changes necessary in planning and designing pharma market access plans, including a revamp of the payer-value equation at pivotal points in the product life cycle.
By Any Genes Necessary: The Role of MEAs for Gene Therapies
Examining why the cost and administration of these treatments are well suited to managed entry agreements—and which approach to MEA may prove to be the most commercially viable for manufacturers.
A Framework for Future: Strengthening Market Access Competencies
The BCG Market Access Roundtable presents an updated view of its access competencies framework first published five years ago.
Value Risk and Reward: Taking Stock of Value-Based Contracts in Pharma
A look at how VBC agreements between drug manufacturers and payers—which reimburse for pre-specified treatment outcomes—have measured up so far in reducing healthcare costs, and the opportunities still untapped to drive true value for both sides and the patients they serve.
Evolve the Role of Reimbursement Policy to Meet the Needs of the New Market Access Ecosystem
Chance Scott shares insights on the benefits of evolving the role and integration of your reimbursement policy team to serve as market access partners and propellants, as well as the best practices for how to do so.
The Foundations of Pharmaceutical Industry Compliance
A focus on medical affairs and medical science liaisons.
Three Ways to Overcome Any Market Challenge
Pandemic-reinforced principles of successful drug launch.
Staying the Course: Double Down on Launch Agility
In today’s fragmented commercial environment, navigating a more complex set of challenges while adapting new approaches to product launch is critical for biopharma brand teams.
Product Analogs Point to Pricing and Distinct Payer Market Scenarios
A business framework for pricing and broader brand strategy.
2 Commerce Drive Cranbury, NJ 08512